FOSUN PHARMA (02196): Drug Registration Application for Vincristine Sulfate Injection Accepted by National Medical Products Administration

Stock News

08/26

FOSUN PHARMA (02196) announced that its controlling subsidiary Gismer (Wuhan) Pharmaceutical Co., Ltd. has recently received acceptance from the National Medical Products Administration for its drug registration application of Vincristine Sulfate Injection (the "Drug").

The Drug is a chemical pharmaceutical independently developed by the Group (referring to the Company and its controlling subsidiaries/entities). It is intended for the treatment of acute leukemia and can also be used in combination with other anti-tumor drugs for treating Hodgkin's lymphoma, non-Hodgkin's malignant lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.

As of July 2025, the Group's cumulative research and development investment for this Drug amounts to approximately RMB 3.03 million (unaudited). According to the latest data from IQVIA CHPA, the sales of vincristine sulfate injection in mainland China (excluding Hong Kong, Macau, and Taiwan) reached approximately RMB 202 million in 2024.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1176183750"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176183750\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176183750?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176183750","market":"hk","top_or_hot":-1,"title":"FOSUN PHARMA (02196): Drug Registration Application for Vincristine Sulfate Injection Accepted by National Medical Products Administration","media":"Stock News","content":"<p>FOSUN PHARMA (02196) announced that its controlling subsidiary Gismer (Wuhan) Pharmaceutical Co., Ltd. has recently received acceptance from the National Medical Products Administration for its drug registration application of Vincristine Sulfate Injection (the \"Drug\").</p>\n<p>The Drug is a chemical pharmaceutical independently developed by the Group (referring to the Company and its controlling subsidiaries/entities). It is intended for the treatment of acute leukemia and can also be used in combination with other anti-tumor drugs for treating Hodgkin's lymphoma, non-Hodgkin's malignant lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.</p>\n<p>As of July 2025, the Group's cumulative research and development investment for this Drug amounts to approximately RMB 3.03 million (unaudited). According to the latest data from IQVIA CHPA, the sales of vincristine sulfate injection in mainland China (excluding Hong Kong, Macau, and Taiwan) reached approximately RMB 202 million in 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA (02196): Drug Registration Application for Vincristine Sulfate Injection Accepted by National Medical Products Administration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA (02196): Drug Registration Application for Vincristine Sulfate Injection Accepted by National Medical Products Administration\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-08-26 21:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>FOSUN PHARMA (02196) announced that its controlling subsidiary Gismer (Wuhan) Pharmaceutical Co., Ltd. has recently received acceptance from the National Medical Products Administration for its drug registration application of Vincristine Sulfate Injection (the \"Drug\").</p>\n<p>The Drug is a chemical pharmaceutical independently developed by the Group (referring to the Company and its controlling subsidiaries/entities). It is intended for the treatment of acute leukemia and can also be used in combination with other anti-tumor drugs for treating Hodgkin's lymphoma, non-Hodgkin's malignant lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.</p>\n<p>As of July 2025, the Group's cumulative research and development investment for this Drug amounts to approximately RMB 3.03 million (unaudited). According to the latest data from IQVIA CHPA, the sales of vincristine sulfate injection in mainland China (excluding Hong Kong, Macau, and Taiwan) reached approximately RMB 202 million in 2024.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"證金概念","start_time":0,"source_url":"","article_id":"1176183750","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176183750","pubTimestamp":1756214074,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (02196) announced that its controlling subsidiary Gismer (Wuhan) Pharmaceutical Co., Ltd. has recently received acceptance from the National Medical Products Administration for its drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0012":"证金概念","BK1593":"医美概念股","BK1191":"制药","BK0175":"白马股","BK0196":"行业龙头","BK0188":"融资融券","BK0060":"抗癌","BK0187":"一线龙头","BK0028":"国家队","02196":"复星医药","BK0239":"医药制造","BK0183":"MSCI概念","BK1515":"抗疫概念","BK0096":"民营医院"},"translate_title":"复星医药(02196)：硫酸长春新碱注射液药品注册申请获国家药品监督管理局受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (02196) announced that its controlling subsidiary Gismer (Wuhan) Pharmaceutical Co., Ltd. has recently received acceptance from the National Medical Products Administration for its drug registration application of Vincristine Sulfate Injection (the \"Drug\").\nThe Drug is a chemical pharmaceutical independently developed by the Group (referring to the Company and its controlling subsidiaries/entities). It is intended for the treatment of acute leukemia and can also be used in combination with other anti-tumor drugs for treating Hodgkin's lymphoma, non-Hodgkin's malignant lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.\nAs of July 2025, the Group's cumulative research and development investment for this Drug amounts to approximately RMB 3.03 million (unaudited). According to the latest data from IQVIA CHPA, the sales of vincristine sulfate injection in mainland China (excluding Hong Kong, Macau, and Taiwan) reached approximately RMB 202 million in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}